Akeso’s Cancer Drug Ivonescimab Shows Promising Trial Results

Akeso, Inc. (HK:9926) has released an update.

Akeso, Inc. has announced the acceptance of their supplemental New Drug Application by China’s National Medical Products Administration for ivonescimab, a novel first-line treatment for non-small cell lung cancer with positive PD-L1 expression, showing promising results in a Phase III clinical trial. Ivonescimab has demonstrated significant improvement in progression-free survival over pembrolizumab monotherapy and is poised to set a new standard in chemo-free lung cancer care. The drug, which is already approved in China for another lung cancer indication, is currently in multiple Phase III trials for various cancer treatments.

For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.